Probiotic Intervention With Elderly Subjects
Randomized Placebo Controlled Study to Assess the Effect of a Probiotic Supplement on the Subclinical Levels of Intestinal C. Difficile Among Elderly
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Turku, Finland
- Elderly Home Kerttuli
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- elderly subjects
- no acute infection at recruitment
Exclusion Criteria:
- antibiotic treatment 1 month prior to beginning of study
- less than 6 month life expectancy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Probiotic
Lactobacillus
|
4 month probiotic intervention with 1 month run-in and 1 month wash-out.
Probiotic given once a day.
Other Names:
|
|
Placebo Comparator: Placebo
Sucrose
|
4 month probiotic intervention with 1 month run-in and 1 month wash-out.
Probiotic given once a day.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in level of faecal Clostridium difficile
Time Frame: 0 weeks, 8 weeks, 16 weeks
|
Quantification of C. difficile from faecal samples
|
0 weeks, 8 weeks, 16 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in nutritional status
Time Frame: 0 weeks, 16 weeks
|
Evaluated according to the Mini Nutritional Assessment (MNA®) questionnaire.
|
0 weeks, 16 weeks
|
|
Change in quality of life
Time Frame: 0 weeks, 16 weeks
|
Evaluated according to the validated 15D© health related survey from adequately oriented subjects.
|
0 weeks, 16 weeks
|
|
Change in levels of other intestinal pathogens than C. difficile
Time Frame: 0 weeks, 8 weeks, 16 weeks
|
Quantified from faecal samples
|
0 weeks, 8 weeks, 16 weeks
|
|
Change in bowel function
Time Frame: 0 weeks, 16 weeks
|
Assessed according to Bristol Stool Form Scale by health care personnel throughout the study
|
0 weeks, 16 weeks
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Matti Viitanen, MD, University of Turku
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
Other Study ID Numbers
- Turku_elderly
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.